[HTML][HTML] JAK inhibitor therapy in a child with inherited USP18 deficiency

F Alsohime, M Martin-Fernandez… - … England Journal of …, 2020 - Mass Medical Soc
F Alsohime, M Martin-Fernandez, MH Temsah, M Alabdulhafid, T Le Voyer, M Alghamdi
New England Journal of Medicine, 2020Mass Medical Soc
Deficiency of ubiquitin-specific peptidase 18 (USP18) is a severe type I interferonopathy.
USP18 down-regulates type I interferon signaling by blocking the access of Janus-
associated kinase 1 (JAK1) to the type I interferon receptor. The absence of USP18 results in
unmitigated interferon-mediated inflammation and is lethal during the perinatal period. We
describe a neonate who presented with hydrocephalus, necrotizing cellulitis, systemic
inflammation, and respiratory failure. Exome sequencing identified a homozygous mutation …
Summary
Deficiency of ubiquitin-specific peptidase 18 (USP18) is a severe type I interferonopathy. USP18 down-regulates type I interferon signaling by blocking the access of Janus-associated kinase 1 (JAK1) to the type I interferon receptor. The absence of USP18 results in unmitigated interferon-mediated inflammation and is lethal during the perinatal period. We describe a neonate who presented with hydrocephalus, necrotizing cellulitis, systemic inflammation, and respiratory failure. Exome sequencing identified a homozygous mutation at an essential splice site on USP18. The encoded protein was expressed but devoid of negative regulatory ability. Treatment with ruxolitinib was followed by a prompt and sustained recovery. (Funded by King Saud University and others.)
The New England Journal Of Medicine